摘要
前列腺癌是全世界男性的第二大致命性肿瘤;在我国,其发病率和死亡率呈逐年上升趋势。多西他赛联合泼尼松是去势抵抗性前列腺癌(CRPC)的一线治疗方案,但患者发生多西他赛耐药后缺乏有效治疗且预后差。目前,针对CRPC多西他赛耐药的研究主要集中在癌基因与信号通路、转录及凋亡因子、非编码RNA上,同时,肿瘤干细胞、细胞自噬也发挥重要作用。因此,探究总结CRPC患者发生多西他赛耐药的分子机制,探索联系各种耐药机制的多重耐药标志物,对临床指导化疗药物选择与合理配伍有重要意义。
Prostate cancer is the second most lethal cancer in the world.In China,the incidence and mortality of prostate cancer are increasing year by year.Docetaxel combined with prednisone is the first-line treatment for castration resistant prostate cancer(CRPC),but there are lack of effective treatment and poor prognosis after developing docetaxel resistance in the patients.The research on docetaxel resistance in CRPC mainly focuses on oncogenes and signal pathways,transcription and apoptosis factors,non-coding RNA,etc.Meanwhile,tumor stem cells and autophagy also play an important role.Therefore,exploring and summarizing the molecular mechanism of docetaxel resistance in CRPC patients,and exploring the multi-drug resistance markers connecting various drug resistance mechanisms are of great significance for guiding the selection and rational combination of chemotherapeutic drugs in clinical practice.
作者
张怡奎
邱晓拂
ZHANG Yikui;QIU Xiaofu(The Second School of Clinical Medicine,Southern Medical University,Guangzhou 510282,China;Department of Urology,Guangdong Second Provincial General Hospital,Guangzhou 510317,China)
出处
《医学综述》
CAS
2023年第9期1738-1744,1751,共8页
Medical Recapitulate
基金
广州市科技计划项目(201904010035)。
